Abstract:

Ｏｂｊｅｃｔｉｖｅ：To observe the clinical efficacy and safety of lenalidomide with dexamethasone (LD) in the treatment of relapse/refractory lightchain amyloidosis.
Ｍｅｔｈｏｄｏｌｏｇｙ：Ten patients diagnosed relapse/refractory lightchain amyloidosis were enrolled in this retrospective study. Their clinical data were reviewed, the hematological and organ responses, treatment related adverse events were analyzed.
Ｒｅｓｕｌｔｓ：Seven males and three females were enrolled with a median age of 645（568，688）years old. Of seven evaluable patients, overall hematological response rate was 429%, including 143% with complete remission. Heart response was seen in two patients,  none had renal response. All were alive and the overall survival and median progression free survival were not reached. Grade 3/4 adverse reaction rate was 30%.
Ｃｏｎｃｌｕｓｉｏｎ：Lenalidomide with dexamethasone was effective and welltolerated as a salvage treatment for relapse/refractory lightchain amyloidosis.

Key words: light-chain amyloidosis, lenalidomide, efficacy, adverse event